EX-99.3 5 ex99_3.htm FACT SHEET WORD ex99_3.htm  (See PDF)
 

PAGE 1
Investor Fact Sheet
Ticker Symbol: CEMI
www.chembio.com

Business Summary & Investment Highlights
Chembio Diagnostics, Inc. (Chembio), through its wholly owned subsidiary Chembio Diagnostic Systems, Inc., develops, manufactures, licenses and markets point-of-care testing (POCT) products. Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create
significant new revenue streams that will add to Chembio’s core business of rapid HIV tests.

• >30% Five Year Revenue CAGR.

• 148% YOY sales increases of Chembio’s FDA approved lateral flow HIV tests that are marketed in the U.S. by Inverness Medical Innovations, Inc. (IMA:NYSE), a leading POCT company. IMA markets Chembio’s products as Clearview® COMPLETE HIV 1/2 globally and Clearview® HIV 1/2 STAT-PAK® in the U.S. to hospital emergency departments, public health clinics, and physicians offices.

• Robust pipeline of POCT products for HIV (oral fluid), Syphilis, Influenza, Hepatitis-C (oral fluid), and other infectious diseases based on Chembio’s patented DPP® technology. Major benefits include improved sensitivity, multiplexing, sample control and quantitative measurements.

• Point-of-care testing is the fastest growing segment of the $40 billion in-vitro diagnostic market. Drive for cost containment and need for quick results have caused the market to grow rapidly.

Selected Financial Information
Stock Information
Ticker Symbol   CEMI
Price 4/30/10  $0.23
52 Week High  $0.39
52 Week Low  $0.10
Outstanding Shares (MM) 62.0
Market Capitalization (MM) $14.26
Fully Diluted (FD) Shares 70.7
Management Holding-FD 11.2
Average Volume (3 Mos) 130,000


Major Beneficial Holders Beneficial Shares Owned (MM)
Lawrence Siebert 6.9
Inverness Medical Innovations, Inc. 5.4
Crestview Capital Offshore Fund, Inc. 3.4


 


Balance Sheet Data ($000s)
Mar.’10
 Dec. '09
Cash
$798
$ 1,068
Accts. Receivable
1,178
1,776
Inventories
1,980
1,556
Other Current Assets
285
267
Total Current Assets
4,241
4,667
Net Fixed Assets
850
580
Other Assets
773
1,068
Total Assets
5,864
6,315
Total Current Liab.
2,810
3,173
Total Other Liab.
46
54
Total Liabilities
2,856
3,227
Total Equity
3,008
3,088
Total Liabilities & Shareholders Equity
$5,864
$ 6,315


Selected Comparative Historical Financial Data
Quarter Ended Year Ended
Three Mos Ended
For the Years Ended
$(000s)
Mar.31, 2010
Mar. 31, 2009
2009
2008
2007
2006
2005
Total Revenues
$  2,783
$ 2 ,546
 $13,834
 $11,050
 $9,231
 $6,503
$3,941
Cost of sales
   1,477
 1,547
      7,974
      7,198
   6,435
      4,894
   2,996
Gross Profit
   1,306
999
      5,860
      3,852
    2,796
      1,609
     945
 
 46.9%
 39.2%
   42.4%
   34.9%
 30.3%
24.7%
24.0%
R&D Expense
                  801
                647
                2,884
               2,605
              1,907
                1,402
              1,365
SG&A Expense
                  661
                676
                2,659
               3,317
              3,765
                4,787
              2,878
Operating Income (Loss)
                (156)
               (324)
                  317
               (2,071)
             (2,876)
              (4,580)
             (3,298)
Other Inc. (Expense)
                   (1)
                  (1)
                  (8)
                122
               249
                (415)
                  46
Net Income (Loss) - Stkhldrs
                (157)
                (325)
                 309
            (1,949)
             (2,627)
              (4,995)
             (3,252)
Pref. Stock Expenses
                    -
                    -
                    -
                   -
              5,645
               3,210
              3,517
Net Loss
               ($157)
($325)
               $ 309
           $ (1,949)
         $ (8,272)
          $(8,205)
            $(6,769)
Net Income (Loss) - per Share
$ 0.00
 $ (0.01)
  $  0.00
 $ (0.03)
 $ (0.57)
 $ (0.80)
$(0.88)
Avg. No. Shares (Millions)
61.986
     61.945
    61.946
    61.267
    14.608
  10.293
7.705
Working capital
 1,431
$1,334
 $1,494
 $1,664
 $3,229
 $5,113
 $831
Total assets
 5,864
   5,697
     6,315
    5,915
  6,585
  7,907
 3,016
Total liabilities
 2,856
   3,429
     3,227
   3,338
  2,322
  2,297
   1,964
Equity (Deficit)
3,008
 2,268
    3,088
   2,577
  4,263
  (940)
   1,053



Chembio Diagnostics, Inc.
3661 Horseblock Road
Medford, NY 11763
Ph. 631-924-1135
Fax 631-924-2065
www.chembio.com

Investor Relations
The Investor Relations Group
James Carbonara, JCarbonara@investorrelationsgroup.com
212-825-3210

Company Contact
Susan Norcott, Snorcott@chembio.com
631-924-1135 x125


 
 
 
PAGE 2 –

Chembio’s Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Inverness Medical Innovations, Inc.

DPP® Technology
Competitive Advantages For POC Testing

• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for   reading and reporting of qualitative or quantitative results

Chembio’s Dual Path Platform (DPP®) Patented in 2007

Senior Management Team
Lawrence A. Siebert, Chairman & CEO, 25 years of management and financing experience
Richard J. Larkin, CFO, 25 years of operational and financial experience
Javan Esfandiari, SVP R&D, 15 years of experience in development of in-vitro point of care products

Board of Directors
Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, INC. (NYSE:CMI)

Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development



Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostics, Inc.'s most recent Form 10-K and Forms 10-Q for additional information about the Company andrelated risks. - May 2010